Brauchen wir immer neue Biomarker?

Literatur
1 DeBeradinis B, Januzzi Jr JL. Use of biomarkers to guide outpatient therapy of heart failure. Curr Opin Cardiol 2012; 27: 661-668
2 Jungbauer CG, Riedlinger J, Buchner S et al. High-sensitive troponin T in chronic heart failure correlates with severity of symptoms, left ventricular dysfunction and prognosis independently from N-terminal pro-b-type natriuretic peptide. Clin Chem Lab Med 2011; 49: 1899-1906
3 Keller T, Zeller T, Peetz D et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009; 361: 868-877
4 Lok DJ, Van Der MP, de la Porte PW et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010; 99: 323-328
5 Maisel A, Mueller C, Adams Jr K et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10: 824-839
6 Maisel A, Mueller C, Nowak RM et al. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2011; 58: 1057-1067
7 McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012; 33: 1787-1847
8 Pascual-Figal DA, Casas T, Ordonez-Llanos J et al. Highly sensitive troponin T for risk stratification of acutely destabilized heart failure. Am Heart J 2012; 163: 1002-1010
9 Pascual-Figal DA, Manzano-Fernandez S, Boronat M et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 2011; 13: 718-725
10 Thygesen K, Alpert JS, Jaffe AS et al. Third universal definition of myocardial infarction. Circulation 2012; 126: 2020-2035